Simponi Seen to Show Promise as Short-Term Treatment for Ulcerative Colitis

Simponi Seen to Show Promise as Short-Term Treatment for Ulcerative Colitis
An observational study of the TNF blocker Simponi (golimumab) in patients with ulcerative colitis found that it is a promising short-term treatment, but a large proportion of patients needed more of it after a few months to keep its benefits. Patients who had not previously taken drugs blocking TNF-alpha were also seen to be more likely to

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *